The proprietary tumor-penetrating technology of DrugCendR Inc. provides a solution to poor solid tumor penetration and limited efficacy of available anti-cancer therapies (small molecules, biologics). Robust validation, works across a broad range of cancer models, a well-understood mechanism of action. Phase I start: H1/2018.
The lead product is the tumor-penetrating peptide CEND-1 (iRGD in scientific literature). Studies by the company founders (out of the laboratory of Dr. Erkki Ruoslahti of Sanford Burnham Prebys Medical Discovery Institute) and by numerous independent groups have shown that CEND-1 is active in diverse tumor models and can improve the antitumor efficacy - and reduce the side effects - of most types of cancer therapeutics. CEND-1 triggers a transport pathway (CendR pathway) in tumors and the surrounding extracellular matrix, enabling an active transportation of drugs selectively into tumor tissues.